Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2007

Amylin and PsychoGenics Create Psychiatric-Focused Company

  • PsychoGenics collaborated with Amylin Pharmaceuticals to form Psylin Neurosciences, a new company that will focus on the discovery and development of peptide hormones for the treatment of psychiatric disorders.

    “The creation of Psylin affords both companies the opportunity to pursue a new area of research, while maintaining their corporate focus," says Emer Leahy, Ph.D., president and CEO of PsychoGenics.

    Both companies participated equally in a Series A financing of Psylin that is anticipated to fund the company for the next two years.

    Under this new venture, Psylin will have access to molecules in Amylin's polypeptide hormone library, Phormol™, and to PsychoGenics' drug discovery technologies. Psylin will also have the right to develop a number of drug candidates emerging from this collaboration.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »